Skip to main content
GHRS
NASDAQ Life Sciences

GH Research Q3: FDA-Aligned Pivotal TRD Design, EoP2 Set for Q1 2027, $350.6M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$18.87
Mkt Cap
$1.269B
52W Low
$12.04
52W High
$31.439
52W Position info
57% above low
Off High info
40% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

GHRS sits 57% above its 52-week low of $12.04.

Summary

GH Research reported a narrower Q3 loss ($12.5M, or $0.18/share) and said final device data support a one-dose-per-visit pivotal design, with an FDA End-of-Phase 2 meeting expected in Q1 2027 and $350.6M in cash to fund it.


Key Events · Product Development and Regulatory · GHRS

  • One-Dose Pivotal Design Backed by Device Data

    Final GH001-HV-106 results support a single fixed dose per treatment visit with the new Aerosol Delivery System, which delivered 82%-89% of the loaded dose in bench testing versus 55%-79% for the old vaporizer; 88% of participants (7 of 8) reached a peak experience at the planned pivotal dose.

  • FDA Feedback Sets Q1 2027 End-of-Phase 2

    Positive initial FDA feedback on a randomized, double-blind, placebo-controlled TRD program with a Week 4 MADRS primary endpoint and 12-week double-blind period; End-of-Phase 2 meeting expected Q1 2027, pivotal initiation shortly after, subject to final alignment.

  • Q3 Loss Narrows to $12.5 Million

    Net loss was $12.5 million, or $0.18 per share, versus $14.0 million ($0.23) in Q3 2025; R&D was $10.1 million and G&A $5.3 million, both slightly lower year over year.

  • Cash of $350.6 Million, No ATM Usage

    Cash, cash equivalents and marketable securities totaled $350.6 million at September 30, 2026, up from $280.7 million at year-end after April's $111.2 million net offering proceeds; no shares had been sold under the $200 million ATM.


Analysis · GHRS · Life Sciences

The quarter itself is unremarkable — net loss actually narrowed to $12.5 million from $14.0 million a year ago and R&D spend was flat. What matters is the clinical roadmap: final HV-106 data show the new GH001 Aerosol Delivery System can deliver one fixed dose per visit with an 88% peak-experience rate (7 of 8) at the dose headed into Phase 3, versus the 1-3 titration doses used in Phase 2b. That simplification, plus positive initial FDA feedback on a randomized, double-blind, placebo-controlled design with a Week 4 MADRS primary endpoint, sets up an End-of-Phase 2 meeting in Q1 2027 and pivotal initiation shortly after. With $350.6 million in cash and marketable securities and no debt, the company is funded well past that milestone, and the hiring of J&J's Spravato development veteran as Chief Development Officer adds execution depth. The main risk is timing: the pivotal program has not started, and the design is not final until the FDA meeting.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GHRS was trading at $18.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $12.04 to $31.44. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GHRS - Latest Insights

GHRS
Aug 06, 2026, 7:24 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $29.08
Real-time Price: $18.87 info
Change: -$10.21 (-35%) info
Market Cap: $1.269B info
GHRS
Jun 04, 2026, 8:35 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $24.56
Real-time Price: $18.87 info
Change: -$5.69 (-23%) info
Market Cap: $1.269B info
GHRS
May 21, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $22.35
Real-time Price: $18.87 info
Change: -$3.48 (-16%) info
Market Cap: $1.269B info
GHRS
May 14, 2026, 9:20 AM EDT
Filing Type: F-3
Importance Score:
8
Price at Filing: $21.57
Real-time Price: $18.87 info
Change: -$2.70 (-13%) info
Market Cap: $1.269B info
GHRS
May 14, 2026, 9:02 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $21.57
Real-time Price: $18.87 info
Change: -$2.70 (-13%) info
Market Cap: $1.269B info